Clinical Research Institute to Save $1M Per Year With SIGNiX Digital Signatures

One of the nation’s largest clinical research programs has chosen to use SIGNiX’s electronic signature service to speed up the consent process for clinical trials.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
One of the nation’s largest clinical research programs has chosen to use SIGNiX’s electronic signature service.

One of the nation’s largest clinical research programs has chosen to use SIGNiX’s electronic signature service.

The faster they can get their consent forms signed, the faster they can complete clinical trials and get real solutions to the people who need them most.

Chattanooga, Tenn. (PRWEB) March 07, 2014

SIGNiX, the most trusted name in digital signatures, today announced that one of the nation’s largest clinical research institutes selected SIGNiX to accelerate and simplify its consent process. SIGNiX’s technology will enable patients and clinical investigators to sign consent forms online from any computer or mobile device.

“It’s not just about efficiency for this research institute. It’s about helping a grandfather with heart disease who’s afraid he’s going to have a heart attack. It’s about helping a single mother suffering from breast cancer who needs a better treatment plan,” said Gary Peat, Senior Vice President of Corporate & Business Development at SIGNiX. “The faster they can get their consent forms signed, the faster they can complete clinical trials and get real solutions to the people who need them most.”

Not only will SIGNiX’s digital signature technology be more convenient for patients, but SIGNiX will also save staff members significant time because documents get sent for signature instantly along with automated reminders that speed the process.

The research institute expects to save more than $1 million each year by switching to a digital consent process. Before choosing SIGNiX, the institute was shipping at least 40,000 documents each year using next-day mail. With SIGNiX, they will not only save on shipping, printing, faxing and filing paper documents but will also be able to re-allocate staff to more productive activities.

SIGNiX’s digital signature technology will also enhance compliance for the research institute. By enabling required fields, the institute can be sure that each document is filled out completely, eliminating errors and repeated processes.

“Missing signatures on consent forms can put the institute’s entire drug trial at risk,” said Jay Jumper, president and CEO of SIGNiX. “With SIGNiX, we can be sure that every document is legally signed and compliant.”

Other important factors that led the research institute to choose SIGNiX included:

  • Standards-based digital signatures
  • Embedded signature verification
  • Flexible signer authentication options
  • Reliable and consistent performance
  • Compliance with regulations set by the Health Insurance Portability and Accountability Act (HIPAA) and by the FDA’s 21 CFR Part 11

The research institute is part of one of the nation’s leading healthcare companies.

About SIGNiX
SIGNiX, the Global Digital Signature AuthorityTM, makes signing documents online safe and secure. SIGNiX offers the only independently verifiable cloud-based digital signature solution, which combines convenience with best-in-class security. SIGNiX’s products help the world’s leading companies become more efficient, decrease risk and boost profits. For more information, visit http://www.signix.com or follow SIGNiX on Twitter.


Contact